Correlation of somatic mutations and clinical outcome in melanoma patients treated with carboplatin, paclitaxel, and sorafenib

PURPOSE: Sorafenib is an inhibitor of VEGFR, PDGFR, and RAF kinases, amongst others. We assessed the association of somatic mutations with clinicopathologic features and clinical outcomes in patients with metastatic melanoma treated on E2603, comparing treatment with carboplatin, paclitaxel +/− sora...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Wilson, Melissa A., Zhao, Fengmin, Letrero, Richard, D’Andrea, Kurt, Rimm, David L., Kirkwood, John M., Kluger, Harriet M., Lee, Sandra J., Schuchter, Lynn M., Flaherty, Keith T., Nathanson, Katherine L.
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4058354/
https://ncbi.nlm.nih.gov/pubmed/24714776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0093
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items